| Name | Title | Contact Details |
|---|
Med-Metrix is a Montvale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Akron Biotechnology is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SI Group is a leading global developer and manufacturer of chemical intermediates, specialty resins and solutions that are critical to the quality and performance of countless industrial and consumer goods. We`re a global leader with a local presence in 10 countries, more than 2,700 employees, and customers in more than 90 countries. Our people, facilities and integrated supply chain deliver products and solutions where our customers need them, when they need them. Our focus is on ten key market segments—rubber resins, antioxidants, fuels and lubricants, plastic additives, industrial resins, health and wellness, adhesive resins, surfactants, engineering plastics and pharma and specialty. We provide solutions that address four global megatrends: a clean environment, diminishing resources, changing patterns in mobility and changing demographics. As the world changes, SI Group will continue supply solutions to increasingly complex problems as a chemistry partner. After all, with more than 100 years of innovation as a foundation, we are paving the way forward for the next generation of chemistry and partnering with our customers to build a better tomorrow.
KBI BioPharma is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vital Therapies, Inc. is a biotherapeutic company focused on developing a cell-based system for the treatment of acute liver failure. Our product candidate, the ELAD® System, is a human cell-based, bio-artificial liver support system that operates outside the body, or extracorporeally, and is designed with the proposed intent to allow the patient’s own liver to regenerate to a healthy state, or to stabilize the patient until liver transplant. The ELAD System incorporates our human liver-derived cells, or VTL C3A cells, contained in four hollow fiber cartridges, that are combined with single use customized disposable sets and an ancillary delivery system. Data from ELAD clinical studies has shown trends that may indicate a potential to increase survival rates in patients with acute liver failure. ELAD has received orphan designation in the United States and Europe for the treatment of acute liver failure. Prior to the initiation of our ongoing Phase III clinical trial program, over 145 subjects have received therapy with the ELAD System in seven clinical trials and through a compassionate use program, which we believe collectively suggests a promising therapeutic profile. In March 2013, we initiated VTI-208, a Phase III randomized, controlled clinical trial in 200 subjects with alcohol-induced liver decompensation. We reached the midpoint in enrollment of this trial in April 2014, and anticipate the release of preliminary data in the first half of 2015. In addition, we are conducting a second Phase III randomized, controlled clinical trial, VTI-210, in 150 subjects with severe acute alcoholic hepatitis, or AAH, which is a subset of AILD, and expect to initiate enrollment of subjects later in 2014. In the second quarter of 2014, we began enrollment of a Phase II clinical trial of the ELAD System in subjects with either fulminant hepatic failure, or FHF, or surgery-induced acute liver failure, or SILF. We anticipate the release of data from VTI-210 in 2016 and the Phase II component of VTI-212 in 2015 or 2016.